Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Angle Plc LSE:AGL London Ordinary Share GB0034330679 ORD 10P
  Price Change % Change Share Price Shares Traded Last Trade
  0.50 0.4% 125.00 224,507 13:26:01
Bid Price Offer Price High Price Low Price Open Price
124.00 126.00 125.00 124.00 124.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.76 -13.75 270
Last Trade Time Trade Type Trade Size Trade Price Currency
17:07:45 O 26,000 125.00 GBX

Angle (AGL) Latest News (3)

More Angle News
Angle Investors    Angle Takeover Rumours

Angle (AGL) Discussions and Chat

Angle (AGL) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-06-24 16:07:45125.0026,00032,500.00O
2021-06-24 15:28:29125.3010,00012,530.00O
2021-06-24 15:27:31124.3013,00016,159.00O
2021-06-24 15:24:33125.0012,10115,126.48O
2021-06-24 15:22:20125.204,0005,008.00O
View all Angle trades in real-time

Angle (AGL) Top Chat Posts

DateSubject
24/6/2021
09:20
Angle Daily Update: Angle Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker AGL. The last closing price for Angle was 124.50p.
Angle Plc has a 4 week average price of 119.50p and a 12 week average price of 80.50p.
The 1 year high share price is 142.50p while the 1 year low share price is currently 37.50p.
There are currently 215,651,845 shares in issue and the average daily traded volume is 344,581 shares. The market capitalisation of Angle Plc is £269,564,806.25.
20/5/2021
07:36
amaretto1: Sky's the limit with AGL ...I've no idea what the value of this company is .. but imo it's multiples of this share price i was a share holder in GW pharma, in the very early stages, and we all can see were they ended up, and AGL is the only company in 30 years of investing trading that comes close.
18/5/2021
12:39
spaceparallax: Let's hope that any hostile takeover can be fended off; big pharma have certainly not been a friend to Angle, if anything, quite the opposite. As the share price continues to rise, so the incentive to sell out will diminish and any hostile attempt would have to accumulate through the open mkt, which would drive the price substantially skywards. Over the years we've experienced dilution through fundraising, but equally the scope and provenance of application has increased exponentially, whereby our MCap is miniscule compared to the potential commercialisation. Given a fair run, it's quite conceivable that we could be trading at many times the current share price in just a few years. This simple but effective system truly has the capability to become one of the major breakthroughs of the 21st century with, unlike many dot.com gimmicks, truly worldwide utility and benevolent application. Parsortix doesn't require marketing gimmicks and spin, its many times proven ability says it all.
11/5/2021
10:38
acuere: Trinity Delta initiated coverage of Maxcyte in 2016 at about 80p, with what looked like a frothy target share price of 184p. share price now 900p with Trinity target now 1217p. Let’s hope for similar success with AGL. More significantly is today’s RNS. This is a huge market for a very tricky disease to treat. Hopefully AGL can play their part in improving survival rates.
30/4/2021
11:29
jelenko: I must say that my investment rationale in AGl has been focused on their mkt cap compared to other companies in the U.S. that had a lot less to offer than AGL and have been taken out at circa $2.5b. Also other companies such as EXAS with a mkt cap of over $22b. So £200m ish is attractive! Not really interested in daily M.Makers shenanigans and minor share price moves. Not really interested in if a buy or sell went through just interested in the fact that I own a portion of this great company that will grow into a large U.S. listed beast and in the process help so many poorly people.
19/4/2021
19:11
gersemi: 'I show below a YouTube link to Andrew Newland, the CEO of Angle (LON:AGL), who here considers last Friday’s announcement of Angle’s success in developing Parsortix, a liquid biopsy system which detects cancer. As most of you know, it is customary to cut the patient open, which is relatively an extremely expensive operation. Parsortix just takes blood and pronounces – although it must be stressed that this approach has yet to be approved by regulatory authorities. However, last Friday’s contract announcement means that AGL has been accepted by a pharma major. This could not have occurred in the absence of the pharma major being reasonably confident that all this would work. AGL is capitalised at 98p at £210m. This is a trifling figure should all go as planned. It is no exaggeration to expect AGL, if successful, to be worth billions of pounds.' (Biographical note: Andrew’s brother, Dr Richard Newland, a former GP, trained a winner of the Grand National – Pineau de Re – in 2014. Andrew is a chartered accountant by upbringing. I met him perhaps five years ago at a presentation arranged by Jeremy Lyon and the late Bob Catto. I liked the cut of his jib. Family Cawkwell own c. 500,000 AGL.) HTTP://masterinvestor.co.uk/evil-diaries/evil-knievil-a-new-angle/
18/4/2021
09:05
tomphys: The increase in share price could happen rapidly. Most traders got cleaned out when it was settling in the 80's in the last 2-3 weeks. And the insiders, institutional holders (conifer etc) along with a lot of LTH have a minimum price they will sell at which is many multiples of the current price. The share price shot up so much Friday pm i was getting dummy quotes to sell for large quantities that was above the asking price. If AN had gave that interview an hour earlier we would have broke 1£
18/4/2021
08:47
purchaseatthetop: molatovkid.....balanced and correct view. Shareholders have spent around £85m in the last years getting us to this point on Friday where the first commercial contract has been disclosed. The CEO seems very confident (almost smugly happy IMO) that there are an array of other contracts coming PDQ. He pointedly suggested (IMO) that simply these pharma contracts without FDA approval completely derisks AGL. The FDA is now the cherry on a very large cake. With a very limited downside at 98p share price and an almost unlimited upside (up to £20+) this is, as you say, a share that I will not be out of. Still completely off the radar. Friday pm share price rise showed that some investors are now becoming aware. Expect radical IMO price rise next week. I am in buying more literally first thing tomorrow.
17/4/2021
17:56
purchaseatthetop: fraybentos.....I may be wrong but I look always at the big picture. My largest investments are in AGL, ITX and ENET (before that MCRO). I think about where a company will be in 2 to 3 years not this year. I care little about forecasts for current year. It is completely clear to me that even without the FDA approval AGL is hugely undervalued. Lets see if I am wrong on that. As you are invested you will be delighted with the recent share price rise....right?
16/4/2021
16:55
iomdm: antonagis, we lth's have listened to AN and other senior personnel suggest £20 to £25 per share for over a decade. That has not changed irrespective of dilution or share price. Be it when there were only 60m shares or when the share price was 18p.
22/3/2021
15:56
diversification: SK As an extension to the link you kindly provided it is clear to see that this is related to the following RNS: https://uk.advfn.com/stock-market/london/angle-AGL/share-news/Angle-PLC-LUNG-CANCER-STUDY-USES-ANGLES-PARSORTIX/79684162 Interestingly as Astrazeneca, referred to as a leading customer in the RNS makes reference to the the inclusion of ctDNA, it is reasonable to assume that in addition to Parsortix being the only CTC platform being used in this study that an ongoing partnership between AZN and Guardant Health could be the other system for the purpose of ctDNA: https://www.globenewswire.com/news-release/2018/12/13/1666887/0/en/Guardant-Health-Partners-with-AstraZeneca-to-Develop-Blood-Based-Companion-Diagnostic-Tests-for-Tagrisso-and-Imfinzi.html Under the terms of this deal GH went on to see a material move in its share price rising from $35 to $97 at its peak and we can all see what has happened since. Not bad for a multi billion dollar company which is unable to offer protein and RNA analysis like AGL, but the exact reason why Parsortix is a useful companion for these major companies. We then consider AGL latest RNS concerning AZN: https://uk.advfn.com/stock-market/london/angle-AGL/share-news/Angle-PLC-Parsortix-Dynamic-assessment-of-patient/84266695 And more specifically AZN's drug Tagrisso which is otherwise a culmination and report on all of the above. What this e-poster and coverage will promise to do is further enhance the Parsortix reputation and help build important new business relationships. In my opinion a deal similar to that of Guardant Health deal in 2018 is more than possible and is perhaps the large Pharma contract that AN recently referred to being announced shortly in a recent presentation.
Angle share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
AGL
Angle
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210625 05:02:12